Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027

ROCKET PHARMACEUTICALS, INC.

Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.
Pipeline focus on AAV cardiovascular programs (Danon, PKP2-ACM, BAG3-DCM) and KRESLADI for severe LAD-I.
Cash runway extended into Q2 2027; excludes any potential proceeds from Priority Review Voucher for KRESLADI.
Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs delayed; FDA OK for RP-L102 no longer expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.